Browsing by Author "Lee, Bonita E"

Now showing 1 - 4 of 4
  • Thumbnail Image
    ItemOpen Access
    Antimicrobial use among adult inpatients at hospital sites within the Canadian Nosocomial Infection Surveillance Program: 2009 to 2016
    (2020-02-13) Rudnick, Wallis; Science, Michelle; Thirion, Daniel J G; Abdesselam, Kahina; Choi, Kelly B; Pelude, Linda; Amaratunga, Kanchana; Comeau, Jeannette L; Dalton, Bruce; Delport, Johan; Dhami, Rita; Embree, Joanne; Émond, Yannick; Evans, Gerald; Frenette, Charles; Fryters, Susan; German, Greg; Grant, Jennifer M; Happe, Jennifer; Katz, Kevin; Kibsey, Pamela; Kosar, Justin; Langley, Joanne M; Lee, Bonita E; Lefebvre, Marie-Astrid; Leis, Jerome A; McGeer, Allison; Neville, Heather L; Simor, Andrew; Slayter, Kathryn; Suh, Kathryn N; Tse-Chang, Alena; Weiss, Karl; Conly, John
    Abstract Background Antimicrobial resistance is a growing threat to the world’s ability to prevent and treat infections. Links between quantitative antibiotic use and the emergence of bacterial resistance are well documented. This study presents benchmark antimicrobial use (AMU) rates for inpatient adult populations in acute-care hospitals across Canada. Methods In this retrospective surveillance study, acute-care adult hospitals participating in the Canadian Nosocomial Infection Surveillance Program (CNISP) submitted annual AMU data on all systemic antimicrobials from 2009 to 2016. Information specific to intensive care units (ICUs) and non-ICU wards were available for 2014–2016. Data were analyzed using defined daily doses (DDD) per 1000 patient days (DDD/1000pd). Results Between 2009 and 2016, 16–18 CNISP adult hospitals participated each year and provided their AMU data (22 hospitals participated in ≥1 year of surveillance; 11 in all years). From 2009 to 2016, there was a significant reduction in use (12%) (from 654 to 573 DDD/1000pd, p = 0.03). Fluoroquinolones accounted for the majority of this decrease (47% reduction in combined oral and intravenous use, from 129 to 68 DDD/1000pd, p < 0.002). The top five antimicrobials used in 2016 were cefazolin (78 DDD/1000pd), piperacillin-tazobactam (53 DDD/1000pd), ceftriaxone (49 DDD/1000pd), vancomycin (combined oral and intravenous use was 44 DDD/1000pd; 7% of vancomycin use was oral), and ciprofloxacin (combined oral and intravenous use: 42 DDD/1000pd). Among the top 10 antimicrobials used in 2016, ciprofloxacin and metronidazole use decreased significantly between 2009 and 2016 by 46% (p = 0.002) and 26% (p = 0.002) respectively. Ceftriaxone (85% increase, p = 0.0008) and oral amoxicillin-clavulanate (140% increase, p < 0.0001) use increased significantly but contributed only a small component (8.6 and 5.0%, respectively) of overall use. Conclusions This study represents the largest collection of dispensed antimicrobial use data among inpatients in Canada to date. Between 2009 and 2016, there was a significant 12% decrease in AMU, driven primarily by a 47% decrease in fluoroquinolone use. Modest absolute increases in parenteral ceftriaxone and oral amoxicillin-clavulanate use were noted but contributed a small amount of total AMU. Ongoing national surveillance is crucial for establishing benchmarks and antimicrobial stewardship guidelines.
  • Thumbnail Image
    ItemOpen Access
    Bordetella pertussis in sporadic and outbreak settings in Alberta, Canada, July 2004 – December 2012
    (BioMed Central, 2014-01-30) Fathima, Sumana; Ferrato, Christina; Lee, Bonita E; Simmonds, Kimberley; Yan, Lin; Mukhi, Shamir N; Li, Vincent; Chui, Linda; Drews, Steven J
  • Thumbnail Image
    ItemOpen Access
    Changes in norovirus genotype diversity in gastroenteritis outbreaks in Alberta, Canada: 2012–2018
    (2019-02-19) Hasing, Maria E; Lee, Bonita E; Qiu, Yuanyuan; Xia, Ming; Pabbaraju, Kanti; Wong, Anita; Tipples, Graham; Jiang, Xi; Pang, Xiaoli L
    Abstract Background The emergence of norovirus genotype GII.4 variants has been associated with gastroenteritis pandemics worldwide, prompting molecular surveillance for early detection of novel strains. In this study, we aimed to analyze the outbreak activity of norovirus and characterize the norovirus strains circulating in Alberta between July 2012 and February 2018. Methods Stool samples from gastroenteritis outbreaks in Alberta were tested for norovirus at the Provincial Laboratory for Public Health using a multiplex real time-RT PCR assay. The ORF1 and ORF2-genotypes of norovirus positive samples were assigned based on phylogenetic analyses of partial polymerase and capsid sequences, respectively. Results A total of 530 norovirus outbreaks were identified. During July 2012 and June 2017 there was a gradual decrease in the annual number of GII.4 outbreaks, however, outbreak numbers increased from June 2017–February 2018. Four novel strains emerged: GII.17 Kawasaki in July 2014–June 2015, GII.P16/GII.4 Sydney in July 2015–June 2016, GII.P16/GII.2 and GII.P4 New Orleans/GII.4 Sydney in July 2016–June 2017. GII.Pe/GII.4 Sydney was the single predominant strain responsible for the majority (over 50%) of all norovirus outbreaks up to June 2015. Between June 2017 and February 2018, GII.P16/GII.4 Sydney was the leading strain causing 63% of all norovirus outbreaks. Conclusions GII.4 stands as the predominant capsid genotype causing a large majority of the norovirus outbreaks in early 2018. An increase in genotype diversity was observed in the last years, characterized by a high circulation of non-GII.4 strains and GII.4 recombinants.
  • Thumbnail Image
    ItemOpen Access
    Identification and Epidemiology of Severe Respiratory Disease due to Novel Swine-Origin Influenza A (H1N1) Virus Infection in Alberta
    (2010-01-01) Zahariadis, George; Joffe, Ari R; Talbot, James; deVilliers, Albert; Campbell, Patricia; Pabbaraju, Kanti; Wong, Sallene; Bastien, Nathalie; Li, Yan; Mitchell, Robyn L; Pang, Xiao-Li; Yanow, Stephanie; Chui, Linda; Predy, Gerald; Willans, David; Lee, Bonita E; Preiksaitis, Jutta K; Clement, Bev; Jacobs, Angela; Jaipaul, Joy; Fonseca, Kevin
    BACKGROUND: In March 2009, global surveillance started detecting cases of influenza-like illness in Mexico. By mid-April 2009, two pediatric patients were identified in the United States who were confirmed to be infected by a novel influenza A (H1N1) strain. The present article describes the first identified severe respiratory infection and the first death associated with pandemic H1N1 (pH1N1) in Canada.METHODS: Enhanced public health and laboratory surveillance for pH1N1 was implemented throughout Alberta on April 24, 2009. Respiratory specimens from all patients with a respiratory illness and travel history or those presenting with a severe respiratory infection requiring hospitalization underwent screening for respiratory viruses using molecular methods. For the first severe case identified and the first death due to pH1N1, histocompatibility leukocyte antigens were compared by molecular methods.RESULTS: The first death (a 39-year-old woman) occurred on April 28, 2009, and on May 1, 2009, a 10-year-old child presented with severe respiratory distress due to pH1N1. Both patients had no travel or contact with anyone who had travelled to Mexico; the cases were not linked. Histocompatibility antigen comparison of both patients did not identify any notable similarity. pH1N1 strains identified in Alberta did not differ from the Mexican strain.CONCLUSION: Rapid transmission of pH1N1 continued to occur in Alberta following the first death and the first severe respiratory infection in Canada, which were identified without any apparent connection to Mexico or the United States. Contact tracing follow-up suggested that oseltamivir may have prevented ongoing transmission of pH1N1.